• Pain management · Mar 2012

    Transdermal buprenorphine in clinical practice: results from a multicenter, noninterventional postmarketing study in Slovenia.

    • Skvarc Nevenka Krcevski NK University Clinical Centre Maribor, Department of Anesthesiology, Intensive Care & Pain Management, Ljubljanska 5, Maribor 2000, Slovenia. neve.
    • University Clinical Centre Maribor, Department of Anesthesiology, Intensive Care & Pain Management, Ljubljanska 5, Maribor 2000, Slovenia. nevenka.krcevski.skvarc@amis.net.
    • Pain Manag. 2012 Mar 1; 2 (2): 177-83.

    UnlabelledSUMMARY AimA 3-month routine clinical practice evaluation of buprenorphine transdermal patch use in Slovenia.Patients & MethodsA prospective, noninterventional, postmarketing study performed by 68 investigators in 42 clinical practice settings. Buprenorphine transdermal patches 35, 52.5 or 70 µg/h were prescribed to patients with chronic moderate-to-severe cancer pain, or chronic severe noncancer pain insufficiently controlled by nonopioid analgesics or weak opioids. At physician discretion, additional analgesia and adjuvant/supportive treatment was allowed.ResultsData were evaluated for 374 patients (56% female, mean age 69 [range 35-100] years), with cancer-related (53%) or noncancer (46%) pain. Reasons for switching to transdermal buprenorphine included intense pain (insufficient pain relief), good prior patient experience with transdermal buprenorphine, adverse reaction or development of tolerance to previous pain therapy, and the beneficial safety profile of transdermal buprenorphine. Mean pain intensity (baseline: 7.4; 0-10 numerical rating scale) was reduced at final assessment (2.3). Pain relief was rated 'very good' or 'good' in 82% of patients at final assessment. Dose stability was good throughout the study; overall, more patients received supportive antiemetics/laxatives during the study than prior to starting transdermal buprenorphine. One hundred and seventy seven nonserious adverse drug reactions (mainly local skin reactions) occurred in 100 (27%) patients. Treatment was discontinued due to unsatisfactory pain relief (4.6%) or adverse drug reactions (7%).ConclusionIn routine Slovenian clinical practice, transdermal buprenorphine provided efficient analgesia and was well-tolerated in patients with chronic moderate-to-severe cancer pain or chronic severe noncancer pain insufficiently controlled by nonopioids and, as the study results indicate, also in chronic severe noncancer pain insufficiently controlled by weak opioids.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.